When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Cassava Stock: Despite Overhangs, the Risk-Reward Looks ... - AOL

   www.aol.com/news/cassava-stock-despite-overhangs...

   The stock tumbled over 20% following a fireside chat, where CEO Remi Barbier outlined the progress being made in bringing simufilam, Cassava’s controversial Alzheimer’s drug candidate, to ...

3. What's Going On With Alzheimer's-Focused Cassava ... - AOL

   www.aol.com/whats-going-alzheimers-focused...

   With the update, HC Wainwright has upgraded Cassava Sciences’ stock from Neutral to Buy, with a price target of $116, an upside of over 290%. In the letter, Rick highlighted completing the ...

4. Why Cassava Sciences Stock Dived by Almost 11% Today - AOL

   www.aol.com/why-cassava-sciences-stock-dived...

   Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive.

5. Cassava Sciences Stock Is Worth Almost 4x More After ... - AOL

   www.aol.com/news/cassava-sciences-stock-worth...

   Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s ...

6. Cassava: Making Big Things Happen? This 5-Star Analyst ... - AOL

   www.aol.com/news/cassava-making-big-things...

   Cassava Sciences (SAVA) hogged the headlines last year both for good and bad reasons. The company’s Alzheimer’s disease (AD) candidate simufilam showed exceptional results in clinical trials ...

7. This Analyst Goes Back to the Future to Recommend Cassava Stock

   www.aol.com/news/analyst-goes-back-future...

   Six months ago Cassava Sciences (SAVA) had a problem. A citizen petition was logged with the FDA calling for a halt on the company's simufilam drug for the treatment of Alzheimer's Disease. The ...